ClinicalTrials.gg
TerminatedNCT02186418Updated Nov 18, 2026Results posted

Gene Transfer for Patients With Sickle Cell Disease

A Phase 1/2 interventional study of ARU-1801 in Anemia, Sickle Cell, sponsored by Children's Hospital Medical Center, Cincinnati. Terminated at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 1/2, Interventional, and Supportive care

How we know

Why this study was terminated
Sponsor decision due to funding
Updated Nov 18, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 11 under way, none of them phase 3. Anemia, Sickle Cell · Children's Hospital Medical Center, Cincinnati.

Enrollment
20th of 21
7 · median 66
Started
2014
with 4 others
Phase 1/2
3 of 30
1 open now
Registered
11th of 30
by date

Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2014, is one of 3 in phase 1/2, and was the 11th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

7 of the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease

Read the detailed description

This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.

03

Conditions studied

  • Anemia, Sickle Cell

Keywords

  • sickle cell disease
  • sickle cell anemia
  • hemoglobinopathies
  • hematopoietic stem cell
  • gene transfer
  • gene therapy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Has confirmed diagnosis of sickle cell disease (SCD)
  • Has severe sickle cell disease, defined as one or more of the following:

    1. Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS) requiring hospital admission, or one life threatening episode of ACS requiring intensive care unit (ICU) admission for exchange transfusion and/or intubation, or frequent ACS episodes which necessitate treatment with chronic transfusion therapy.
    2. Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere with normal life activities, defined as a history of 2 or more severe acute sickle pain events per year requiring additional treatment at a medical facility outside of home pain management over the preceding 2-year period prior to study enrollment, or that necessitate chronic transfusion therapy.
    3. Subjects on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities.
  • Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has actively made the choice to not take the recommended daily hydroxyurea advised for severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell collection). If refusing hydroxyurea, the subject must document that they have been educated about the benefits and continue to refuse the treatment. Patients placed on chronic transfusion therapy instead of hydroxyurea for severe disease are eligible. Subjects unable to take hydroxyurea due to financial or safety monitoring constraints are eligible.
  • Has adequate functional status and organ function as determined at Screening.

Exclusion criteria

Exclusion Criteria

  • Female subjects who are pregnant or lactating/breastfeeding.
  • Female subjects who are not surgically sterile, or who refuse to practice effective method of as determined by the Investigator for one year after receiving the study drug. Women must also agree not to breastfeed for 1 year after receiving the study drug.
  • Any participant of who refuses to agree to use an appropriate contraceptive method determined by the Investigator, for 1 year after receiving the study drug.
  • Patients with an active malignant disease or receiving treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin).
  • Current diagnosis or history of , , or .
  • Has received another study drug within 30 days, or 5 half-lives of the last dose (whichever is longer), prior to screening.
  • Has severe obstruction, restriction or diffusion defect on pulmonary function tests.
  • Has uncontrolled bacterial, viral or fungal infections within 1 month prior to starting the conditioning part of the study. Subjects with fever should wait for symptoms to resolve before starting the conditioning part of the study.
  • Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving chronic transfusions or hydroxyurea for primary prevention of stroke; has severe cerebral vasculopathy defined as moderate stenosis in >2 arterial segments; and/or has sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of Moyamoya-like disease).
  • Patients with alpha thalassemia sickle cell disease.
  • Has previous liver showing cirrhosis, bridging hepatic fibrosis, or active hepatitis; or has received chronic transfusions and has previous evidence of iron overload and evidence of liver fibrosis by noninvasive liver imaging.
  • Has a matched sibling donor, unless the subject has declined this option or this option is not feasible. Documentation must be included as part of the process for subjects who decline this option.
  • Has a known to any study treatments (e.g. melphalan, plerixafor).

Other protocol-defined inclusion-exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    ARU-1801

    Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.

    Genetic: ARU-1801

Interventions

  • GeneticARU-1801

    Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector * Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor * Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3 Allergic Reaction

    Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product

    Time frame: From infusion (Day 0) to 30 days post-infusion

  2. Number of Participants Grade 4 Infection

    Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days

    Time frame: From infusion (Day 0) to 30 days post-infusion

  3. Total Number of Grade 4 Neutropenia

    Number of participants with Grade 4 neutropenia lasting \>1 month following melphalan

    Time frame: From date of chemotherapy clearance visit to to 30 days post-infusion

  4. Number of Participants With Grade 3 or 4 Toxicity Events

    Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures

    Time frame: From infusion (Day 0) to 30 days post-infusion

  5. Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)

    Time frame: From infusion (Day 0) to 30 days post-infusion

  6. Number of Death Due to Study Procedures

    Time frame: From screening to the end of study, and up to 12 months.

  7. Number of Hematological Malignancy

    Number of hematological malignancy due to vector insertion

    Time frame: From infusion (Day 0) to end of study, up to 12 months

  8. Number of Hematological Cancer

    Number of hematological cancer related to investigational product or study medications/procedures

    Time frame: From infusion (Day 0) to end of study, up to 12 months.

  9. Time to Neutrophil Recovery

    Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) \< 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL)

    Time frame: From infusion (Day 0) to end of study, up to 12 months.

  10. Time to Platelet Recovery

    Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count \< 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days \> 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days)

    Time frame: From infusion (Day 0) to end of study, up to 12 months.

  11. ≥8x10⁶kg Viable CD34+ Cells

    Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells

    Time frame: Date of Enrollment to Infusion (day 0).

  12. ≥4x10⁶ CD34+ Cells/kg Body Weight Transduced

    Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced

    Time frame: Date of Enrollment to Infusion (day 0).

  13. Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells

    Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells

    Time frame: Infusion (Day 0) to 1 year post infusion.

Secondary outcomes

  1. Percentage of HBF^G16D

    Percentage of HBF\^G16D relative to total Hemoglobin

    Time frame: Infusion to 12 months post-infusion

  2. Change in Proportion of Antisickling/Sickling Hemoglobin

    Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome.

    Time frame: Enrollment to Month 24

  3. Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)

    This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry.

    Time frame: Infusion to 12 months post-infusion

  4. Percent VCN at 6 Months

    This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR).

    Time frame: Infusion to 6 months post-infusion

07

Results

Posted Nov 18, 2026

Participant flow

Identification and Referral: Potential participants were identified through clinical referral. Hematologists at CCHMC and regional partner institutions referred patients based on primary diagnosis and preliminary eligibility criteria. Setting and Duration: All clinical evaluations, interventions, and follow-up visits were performed at Cincinnati Children's Hospital Medical Center. Accrual Period: The active enrollment and treatment window spanned from July 2014 through October 2022.

Participant flow — Overall Study
MilestoneExperimental: ARU-1801
Started7
Completed6
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Grade 3 Allergic Reaction

Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product

Time frame:
From infusion (Day 0) to 30 days post-infusion
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 Allergic Reaction
Participants7 Patients Treated.
Number of Participants With Grade 3 Allergic Reaction0
PrimaryNumber of Participants Grade 4 Infection

Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days

Time frame:
From infusion (Day 0) to 30 days post-infusion
Reported as:
Number · Events
Number of Participants Grade 4 Infection
Events7 Patients Treated.
Number of Participants Grade 4 Infection0
PrimaryTotal Number of Grade 4 Neutropenia

Number of participants with Grade 4 neutropenia lasting \>1 month following melphalan

Time frame:
From date of chemotherapy clearance visit to to 30 days post-infusion
Reported as:
Count of participants · Participants
Total Number of Grade 4 Neutropenia
Participants7 Patients Treated.
Total Number of Grade 4 Neutropenia0
PrimaryNumber of Participants With Grade 3 or 4 Toxicity Events

Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures

Time frame:
From infusion (Day 0) to 30 days post-infusion
Reported as:
Number · Participants with events
Number of Participants With Grade 3 or 4 Toxicity Events
Participants with events7 Patients Treated.
Number of Participants With Grade 3 or 4 Toxicity Events0
Statistical analysis
  • 7 Patients Treated. · Fisher Exact was the planned statistical method per the SAP, however no events occurred in the reporting timeframe.
PrimaryTotal Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Time frame:
From infusion (Day 0) to 30 days post-infusion
Reported as:
Number · Events
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Events7 Patients Treated.
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)283
PrimaryNumber of Death Due to Study Procedures
Time frame:
From screening to the end of study, and up to 12 months.
Reported as:
Count of participants · Participants
Number of Death Due to Study Procedures
Participants7 Patients Treated.
Number of Death Due to Study Procedures0
PrimaryNumber of Hematological Malignancy

Number of hematological malignancy due to vector insertion

Time frame:
From infusion (Day 0) to end of study, up to 12 months
Reported as:
Count of participants · Participants
Number of Hematological Malignancy
Participants7 Patients Treated.
Number of Hematological Malignancy0
PrimaryNumber of Hematological Cancer

Number of hematological cancer related to investigational product or study medications/procedures

Time frame:
From infusion (Day 0) to end of study, up to 12 months.
Reported as:
Count of participants · Participants
Number of Hematological Cancer
Participants7 Patients Treated.
Number of Hematological Cancer0
PrimaryTime to Neutrophil Recovery

Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) \< 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL)

Time frame:
From infusion (Day 0) to end of study, up to 12 months.
Reported as:
Mean · Days
Time to Neutrophil Recovery
Days7 Patients Treated.
Time to Neutrophil Recovery8 ± 1
PrimaryTime to Platelet Recovery

Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count \< 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days \> 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days)

Time frame:
From infusion (Day 0) to end of study, up to 12 months.
Reported as:
Mean · Days
Time to Platelet Recovery
Days7 Patients Treated.
Time to Platelet Recovery4.4 ± 2.2
Primary≥8x10⁶kg Viable CD34+ Cells

Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells

Time frame:
Date of Enrollment to Infusion (day 0).
Reported as:
Count of participants · Participants
≥8x10⁶kg Viable CD34+ Cells
Participants7 Patients Treated.
≥8x10⁶kg Viable CD34+ Cells5
Primary≥4x10⁶ CD34+ Cells/kg Body Weight Transduced

Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced

Time frame:
Date of Enrollment to Infusion (day 0).
Reported as:
Count of participants · Participants
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
Participants7 Patients Treated.
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced6
PrimaryNumber of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells

Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells

Time frame:
Infusion (Day 0) to 1 year post infusion.
Reported as:
Count of participants · Participants
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
Participants7 Patients Treated.
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells7
SecondaryPercentage of HBF^G16D

Percentage of HBF\^G16D relative to total Hemoglobin

Time frame:
Infusion to 12 months post-infusion
Reported as:
Mean · Percent
Percentage of HBF^G16D
Percent7 Patients Treated.
Percentage of HBF^G16D19 ± 0.1
SecondaryChange in Proportion of Antisickling/Sickling Hemoglobin

Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome.

Time frame:
Enrollment to Month 24
Reported as:
Mean · Percent antisickling/sickling hemoglobin
Change in Proportion of Antisickling/Sickling Hemoglobin
Percent antisickling/sickling hemoglobin7 Patients Treated.
Change in Proportion of Antisickling/Sickling Hemoglobin19.2 ± 7.8
SecondaryPercentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)

This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry.

Time frame:
Infusion to 12 months post-infusion
Reported as:
Mean · Percent
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
Percent7 Patients Treated.
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)68 ± 20
SecondaryPercent VCN at 6 Months

This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR).

Time frame:
Infusion to 6 months post-infusion
Reported as:
Mean · Percent
Percent VCN at 6 Months
Percent7 Patients Treated.
Percent VCN at 6 Months36 ± 20

Adverse events

Collected over Adverse events enrollment through 30 days post infusion. All cause mortality screening to end of the study, up to 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
7 Patients Treated.0/7 (0%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Most frequent serious events
Event7 Patients Treated.
Vaso-occlusive painful crisisBlood and lymphatic system disorders3/7
Most frequent other events
Showing 10 of 121
Most frequent other events
Event7 Patients Treated.
Sickle Cell CrisisBlood and lymphatic system disorders7/7
PainGeneral disorders and administration site conditions7/7
InfectionInfections and infestations7/7
Decreased LymphocytesInvestigations7/7
Decreased PlateletsInvestigations7/7
HeadacheNervous system disorders7/7
Decreased Abs NeutrophilInvestigations6/7
PyrexiaGeneral disorders and administration site conditions5/7
AlopeciaSkin and Subcutaneous Tissue disorders5/7
DiarrhoeaGastrointestinal disorders4/7

Baseline characteristics

The analysis population includes all seven (7) enrolled participants with a confirmed diagnosis of severe sickle cell disease who underwent successful mobilization and apheresis, received myeloablative conditioning, and were administered one intravenous infusion of autologous CD34+ cells transduced with the Gamma Globin Lentivirus Vector.

Age, Categorical
Age, Categorical(Participants)ARU-1801
<=18 years0
Between 18 and 65 years7
>=65 years0
Age, Continuous
Age, Continuous(Years)ARU-1801
Mean22 (19 to 34)
Sex: Female, Male
Sex: Female, Male(Participants)ARU-1801
Female6
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARU-1801
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ARU-1801
United States7
08

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
09

References and documents

Publications

  • Grimley M, Davies SM, Shrestha A, Shova A, Asnani M, Kent M, Sayani F, Quinn CT, Niss O, Lutzko C, Mehta PA, Khandelwal P, Little C, Chandra S, Felker S, Chi M, Kalfa TA, Knight-Madden J, Arumugam PI, Ramos KN, Witting S, Latham T, Bushman FD, Malik P. Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nat Med. 2025 Jul;31(7):2204-2212. doi: 10.1038/s41591-025-03662-2. Epub 2025 May 26. PubMed 40419809 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Oct 2022, 99 months.

Results were first posted in Nov 2026, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2014
First posted
Jul 10, 2014
StartActual
Jul 2014
Primary completionActual
Oct 31, 2022
CompletionActual
Oct 31, 2022
Results first posted
Nov 18, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 18, 2026
Primary outcomes
13 edited, 1 removed
What changed in the outcomes
  • EditedIncidenceNumber of Participants With Grade 3 allergic reactionAllergic ReactionTime frame: From infusion (Day 0) to 15 years → From infusion (Day 0) to 30 days post-infusion
  • EditedIncidenceNumber of Participants Grade 4 infectionInfectionTime frame: From infusion (Day 0) to 15 years → From infusion (Day 0) to 30 days post-infusion
  • EditedIncidenceTotal Number of Grade 4 neutropeniaNeutropeniaTime frame: From date of chemotherapy clearance visit to 15 years post-infusion of transduced cells → From date of chemotherapy clearance visit to to 30 days post-infusion
  • EditedIncidenceNumber of Participants With Grade 3 or 4 organ toxicityToxicity EventsTime frame: From screening to 15 years post-infusion of transduced cells → From infusion (Day 0) to 30 days post-infusion
  • EditedIncidenceTotal Number of Adverse Events (AEs) and Serious Adverse Events (SAE)Time frame: From screening to 15 years post-infusion of transduced cells → From infusion (Day 0) to 30 days post-infusion
  • EditedIncidenceNumber of death dueDeath Due to study proceduresStudy ProceduresTime frame: From screening to 15 years post-infusion of transduced cells → From screening to the end of study, and up to 12 months.
  • EditedIncidenceNumber of hematological malignancyHematological MalignancyTime frame: From infusion (Day 0) to 15 years → From infusion (Day 0) to end of study, up to 12 months
  • EditedIncidenceNumber of hematological cancerHematological CancerTime frame: From screening to 15 years post-infusion of transduced cells → From infusion (Day 0) to end of study, up to 12 months.
  • EditedTime to neutrophil recoveryNeutrophil RecoveryTime frame: From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells → From infusion (Day 0) to end of study, up to 12 months.
  • EditedTime to platelet recoveryPlatelet RecoveryTime frame: From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells → From infusion (Day 0) to end of study, up to 12 months.
  • Edited≥8x10⁶kg viableViable CD34+ cellsCellsTime frame: Up to Year 2 → Date of Enrollment to Infusion (day 0).
  • Edited≥4x10⁶ CD34+ cellsCells/kg body weight transducedBody Weight TransducedTime frame: Up to Year 2 → Date of Enrollment to Infusion (day 0).
  • EditedNumber of Subjects With Bone marrow aspirates withMarrow Aspirates With ≥1% geneGene-marked cellsCellsTime frame: Infusion (Day 0) to 1 year → Infusion (Day 0) to 1 year post infusion.
  • RemovedIncidence of Serious Adverse Events (SAEs)Time frame: From screening to 15 years post-infusion of transduced cells
Nov 18, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40419809 ↗
Nov 18, 2026
Secondary outcomes
2 edited, 2 added, 8 removed
What changed in the outcomes
  • EditedChange in proportionProportion of antisicklingAntisickling/sickling hemoglobinSickling HemoglobinTime frame: Baseline to Month 6 through 12 → Enrollment to Month 24
  • EditedPercentage of F-RBCretics (fetal hemoglobin contentFetal Hemoglobin Content in red blood cellsReticulocytes)Time frame: Months 6, 12, 18, 24, 36 → Infusion to 12 months post-infusion
  • AddedPercentage of HBF^G16DTime frame: Infusion to 12 months post-infusion
  • AddedPercent VCN at 6 MonthsTime frame: Infusion to 6 months post-infusion
  • RemovedQuantity of Hb (hemoglobin) subtypesTime frame: Months 6, 12, 18, 24 and year 3, 4, 5
  • RemovedPercentage of F-retics (fetal hemoglobin content in reticulocytes)Time frame: Months 6, 12, 18, 24, 36
  • RemovedPresence of vector copies in white blood cell fractionTime frame: Days 30, 60, 90, Months 4, 5, 6, 9, 12, 18, 21, 24
  • RemovedPresence of vector copies in bone marrowTime frame: Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36
  • RemovedPresence of gene-marked colony-forming unit cells (CFU-c) in bone marrow (BM) indicting gene transferTime frame: Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36
  • RemovedNumber of annualized vaso-occlusive episodes (VOEs) pre-transplant versus post-transplantTime frame: Baseline to year 15
  • RemovedFrequency of opioid use pre-transplant versus post-transplantTime frame: Baseline to year 15
  • RemovedChange in QoL (Quality of Life)Time frame: Baseline, month 4, 5, 6, 12 and 24 and year 3, 4, 5
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40419809 ↗
    Primary outcomes 13 edited, 1 removed
    What changed in the outcomes
    • EditedIncidenceNumber of Participants With Grade 3 allergic reactionAllergic ReactionTime frame: From infusion (Day 0) to 15 years → From infusion (Day 0) to 30 days post-infusion
    • EditedIncidenceNumber of Participants Grade 4 infectionInfectionTime frame: From infusion (Day 0) to 15 years → From infusion (Day 0) to 30 days post-infusion
    • EditedIncidenceTotal Number of Grade 4 neutropeniaNeutropeniaTime frame: From date of chemotherapy clearance visit to 15 years post-infusion of transduced cells → From date of chemotherapy clearance visit to to 30 days post-infusion
    • EditedIncidenceNumber of Participants With Grade 3 or 4 organ toxicityToxicity EventsTime frame: From screening to 15 years post-infusion of transduced cells → From infusion (Day 0) to 30 days post-infusion
    • EditedIncidenceTotal Number of Adverse Events (AEs) and Serious Adverse Events (SAE)Time frame: From screening to 15 years post-infusion of transduced cells → From infusion (Day 0) to 30 days post-infusion
    • EditedIncidenceNumber of death dueDeath Due to study proceduresStudy ProceduresTime frame: From screening to 15 years post-infusion of transduced cells → From screening to the end of study, and up to 12 months.
    • EditedIncidenceNumber of hematological malignancyHematological MalignancyTime frame: From infusion (Day 0) to 15 years → From infusion (Day 0) to end of study, up to 12 months
    • EditedIncidenceNumber of hematological cancerHematological CancerTime frame: From screening to 15 years post-infusion of transduced cells → From infusion (Day 0) to end of study, up to 12 months.
    • EditedTime to neutrophil recoveryNeutrophil RecoveryTime frame: From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells → From infusion (Day 0) to end of study, up to 12 months.
    • EditedTime to platelet recoveryPlatelet RecoveryTime frame: From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells → From infusion (Day 0) to end of study, up to 12 months.
    • Edited≥8x10⁶kg viableViable CD34+ cellsCellsTime frame: Up to Year 2 → Date of Enrollment to Infusion (day 0).
    • Edited≥4x10⁶ CD34+ cellsCells/kg body weight transducedBody Weight TransducedTime frame: Up to Year 2 → Date of Enrollment to Infusion (day 0).
    • EditedNumber of Subjects With Bone marrow aspirates withMarrow Aspirates With ≥1% geneGene-marked cellsCellsTime frame: Infusion (Day 0) to 1 year → Infusion (Day 0) to 1 year post infusion.
    • RemovedIncidence of Serious Adverse Events (SAEs)Time frame: From screening to 15 years post-infusion of transduced cells
    Secondary outcomes 2 edited, 2 added, 8 removed
    What changed in the outcomes
    • EditedChange in proportionProportion of antisicklingAntisickling/sickling hemoglobinSickling HemoglobinTime frame: Baseline to Month 6 through 12 → Enrollment to Month 24
    • EditedPercentage of F-RBCretics (fetal hemoglobin contentFetal Hemoglobin Content in red blood cellsReticulocytes)Time frame: Months 6, 12, 18, 24, 36 → Infusion to 12 months post-infusion
    • AddedPercentage of HBF^G16DTime frame: Infusion to 12 months post-infusion
    • AddedPercent VCN at 6 MonthsTime frame: Infusion to 6 months post-infusion
    • RemovedQuantity of Hb (hemoglobin) subtypesTime frame: Months 6, 12, 18, 24 and year 3, 4, 5
    • RemovedPercentage of F-retics (fetal hemoglobin content in reticulocytes)Time frame: Months 6, 12, 18, 24, 36
    • RemovedPresence of vector copies in white blood cell fractionTime frame: Days 30, 60, 90, Months 4, 5, 6, 9, 12, 18, 21, 24
    • RemovedPresence of vector copies in bone marrowTime frame: Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36
    • RemovedPresence of gene-marked colony-forming unit cells (CFU-c) in bone marrow (BM) indicting gene transferTime frame: Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36
    • RemovedNumber of annualized vaso-occlusive episodes (VOEs) pre-transplant versus post-transplantTime frame: Baseline to year 15
    • RemovedFrequency of opioid use pre-transplant versus post-transplantTime frame: Baseline to year 15
    • RemovedChange in QoL (Quality of Life)Time frame: Baseline, month 4, 5, 6, 12 and 24 and year 3, 4, 5
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02186418
Responsible party
Sponsor
First posted
Jul 10, 2014
Start date
Jul 2014
Primary completion
Oct 31, 2022
Completion
Oct 31, 2022
Results posted
Nov 18, 2026
Last update
Nov 18, 2026

Study contacts

Stella M. Davies, MB BS, PhD, MRCP
study chair · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion